‘Dawn of oral ther­a­py’: Mor­phic touts UC da­ta in march to­ward Take­da’s En­tyvio

The ul­cer­a­tive col­i­tis R&D space is heat­ing up once again, as Mor­phic Ther­a­peu­tic tout­ed pos­i­tive mid-stage da­ta for its oral med.

At week 12, the small mol­e­cule MORF-057 met the study’s pri­ma­ry goal by show­ing a sta­tis­ti­cal­ly sig­nif­i­cant 6.4-point re­duc­tion on a score known as the Ro­barts Histopathol­o­gy In­dex, good for a p-val­ue of p=0.002. The biotech hopes it will be an eas­i­er op­tion for pa­tients than Take­da’s in­tra­venous En­tyvio.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER